Structure–Activity Relationship Studies for Multitarget Antithrombotic Drugs

References

• Schneider DJ , SobelBE. Conundrums in the combined use of anticoagulants and antiplatelet drugs. Circulation116 (3), 305–315 (2007).
   PubMed Web of Science ®Google Scholar
• Levine GN , BatesER, BlankenshipJCet al. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines and the Society for Cardiovascular Angiography and interventions. Circulation124 (23), e574–e651 (2011).
   PubMed Web of Science ®Google Scholar
• Perez-Gomez F , AlegriaE, BerjonJet al. Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J. Am. Coll. Cardiol.44 (8), 1557–1566 (2004).
   PubMed Web of Science ®Google Scholar
• Simi A . Heparin as an immunosuppressant: therapeutic potential beyond anticoagulation. Glycobiology1 (2), 2 (2012).
   Google Scholar
• Camerer E , QaziAA, DuongDN, CornelissenI, AdvinculaR, CoughlinSR. Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood104 (2), 397–401 (2004).
   PubMed Web of Science ®Google Scholar
• Varki NM , VarkiA. Heparin inhibition of selectin-mediated interactions during the hematogenous phase of carcinoma metastasis: rationale for clinical studies in humans. Semin. Thromb. Hemost.28 (1), 53–66 (2002).
   PubMed Web of Science ®Google Scholar
• Wang L , BrownJR, VarkiA, EskoJD. Heparin’s anti-inflammatory effects require glucosamine 6-O-sulfation and are mediated by blockade of L-and P-selectins. J. Clin. Invest.110 (1), 127–136 (2002).
   PubMed Web of Science ®Google Scholar
• Chiodelli P , BugattiA, UrbinatiC, RusnatiM. Heparin/heparan sulfate proteoglycans glycomic interactome in angiogenesis: biological implications and therapeutical use. Molecules20 (4), 6342–6388 (2015).
   PubMed Web of Science ®Google Scholar
• Paliwal R , PaliwalSR, AgrawalGP, VyasSP. Recent advances in search of oral heparin therapeutics. Med. Res. Rev.32 (2), 388–409 (2012).
   PubMed Web of Science ®Google Scholar
• Morphy R , KayC, RankovicZ. From magic bullets to designed multiple ligands. Drug Discov. Today9 (15), 641–651 (2004).
   PubMed Web of Science ®Google Scholar
• Nar H , BauerM, SchmidAet al. Structural basis for inhibition promiscuity of dual specific thrombin and factor Xa blood coagulation inhibitors. Structure9 (1), 29–37 (2001).
   PubMed Web of Science ®Google Scholar
• Morphy R , RankovicZ. Designing multiple ligands – medicinal chemistry strategies and challenges. Curr. Pharm. Des.15 (6), 587–600 (2009).
   PubMed Web of Science ®Google Scholar
• Ilić M , KikeljD, IlašJ. Multitarget antithrombotic drugs. Curr. Top. Med. Chem.11 (22), 2834–2848 (2011).
   PubMed Web of Science ®Google Scholar
• Hoffman M , MonroeDM3rd. A cell-based model of hemostasis. Thromb. Haemost.85 (6), 958–965 (2001).
   PubMed Web of Science ®Google Scholar
• Kranjc A , KikeljD. Dual inhibitors of the blood coagulation enzymes. Curr. Med. Chem.11 (19), 2535–2547 (2004).
   PubMed Web of Science ®Google Scholar
• Weitz JI . Factor Xa and thrombin as targets for new oral anticoagulants. Thromb. Res.127 (Suppl. 2), S5–S12 (2011).
   PubMed Web of Science ®Google Scholar
• Gould WR , McclanahanTB, WelchKMet al. Inhibitors of blood coagulation Factors Xa and IIa synergize to reduce thrombus weight and thrombin generation in vivo and in vitro. J. Thromb. Haemost.4 (4), 834–841 (2006).
   PubMed Web of Science ®Google Scholar
• Nar H . The role of structural information in the discovery of direct thrombin and Factor Xa inhibitors. Trends Pharmacol. Sci.33 (5), 279–288 (2012).
   PubMed Web of Science ®Google Scholar
• Bhunia SS , RoyKK, SaxenaAK. Profiling the structural determinants for the selectivity of representative Factor-Xa and thrombin inhibitors using combined ligand-based and structure-based approaches. J. Chem. Inf. Model.51 (8), 1966–1985 (2011).
   PubMed Web of Science ®Google Scholar
• Frédérick R , RobertS, CharlierCet al. 3,6-Disubstituted coumarins as mechanism-based inhibitors of thrombin and Factor Xa. J. Med. Chem.48 (24), 7592–7603 (2005).
   PubMed Web of Science ®Google Scholar
• Deng JZ , McmastersDR, RabbatPMet al. Development of an oxazolopyridine series of dual thrombin/Factor Xa inhibitors via structure-guided lead optimization. Bioorg. Med. Chem. Lett.15 (20), 4411–4416 (2005).
   PubMed Web of Science ®Google Scholar
• Dönnecke D , SchweinitzA, SturzebecherAet al. From selective substrate analogue Factor Xa inhibitors to dual inhibitors of thrombin and Factor Xa. Part 3. Bioorg. Med. Chem. Lett.17 (12), 3322–3329 (2007).
   PubMed Web of Science ®Google Scholar
• Young RJ , BrownD, Burns-KurtisCLet al. Selective and dual action orally active inhibitors of thrombin and Factor Xa. Bioorg. Med. Chem. Lett.17 (10), 2927–2930 (2007).
   PubMed Web of Science ®Google Scholar
• Petitou M , Nancy-PorteboisV, DubreucqGet al. From heparin to EP217609: the long way to a new pentasaccharide-based neutralisable anticoagulant with an unprecedented pharmacological profile. Thromb. Haemost.102 (5), 804–810 (2009).
   PubMed Web of Science ®Google Scholar
• Meneyrol J , FollmannM, LassalleGet al. 5-chlorothiophene-2-carboxylic acid [(S)-2-[2-methyl-3-(2-oxopyrrolidin-1-yl)benzenesulfonylamino]-3-(4-methylpiperazin-1-yl)-3-oxopropyl]amide (SAR107375), a selective and potent orally active dual thrombin and Factor Xa inhibitor. J. Med. Chem.56 (23), 9441–9456 (2013).
   PubMed Web of Science ®Google Scholar
• Trstenjak U , IlašJ, KikeljD. Transformation of a selective Factor Xa inhibitor rivaroxaban into a dual Factor Xa/thrombin inhibitor by modification of the morpholin-3-one moiety. MedChemComm5 (2), 197–202 (2014).
   Web of Science ®Google Scholar
• Hanessian S , TherrienE, GranbergK, NilssonI. Targeting thrombin and Factor VIIa: design, synthesis, and inhibitory activity of functionally relevant indolizidinones. Bioorg. Med. Chem. Lett.12 (20), 2907–2911 (2002).
   PubMed Web of Science ®Google Scholar
• Carroll AR , PierensGK, FechnerGet al. Dysinosin A: a novel inhibitor of Factor VIIa and thrombin from a new genus and species of Australian sponge of the family Dysideidae. J. Am. Chem. Soc.124 (45), 13340–13341 (2002).
   PubMed Web of Science ®Google Scholar
• Carroll AR , BuchananMS, EdserA, HydeE, SimpsonM, QuinnRJ. Dysinosins B–D, inhibitors of factor VIIa and thrombin from the Australian sponge Lamellodysidea chlorea. J. Nat. Prod.67 (8), 1291–1294 (2004).
   PubMed Web of Science ®Google Scholar
• Young WB , KolesnikovA, RaiRet al. Optimization of a screening lead for factor VIIa/TF. Bioorg. Med. Chem. Lett.11 (17), 2253–2256 (2001).
   PubMed Web of Science ®Google Scholar
• Klinger O , ZollerG, DefossaE, FahadA-O, WalserA, OstremJ. EP-1095933 (2001).
   Google Scholar
• Mederski W , JuraszykH, DorschDet al. WO02070471 (2002).
   Google Scholar
• Juraszyk H , DorschD, MederskiW, BarnesC, TsaklakidisC, GleitzJ. WO0206269 (2002).
   Google Scholar
• Mederski W , JuraszykH, DorschD, TsaklakidisC, GleitzJ, BarnesC. WO0210127 (2002).
   Google Scholar
• Dorsch D , MederskiW, TsaklakidisC, CezanneB, GleitzJ, BarnesC. WO02057236 (2002).
   Google Scholar
• Dorsch D , MederskiW, TsaklakidisC, CezanneB, GleitzJ, BarnesC. WO0248099 (2002).
   Google Scholar
• Smallheer JM , AlexanderRS, WangJet al. SAR and Factor IXa crystal structure of a dual inhibitor of Factors IXa and Xa. Bioorg. Med. Chem. Lett.14 (21), 5263–5267 (2004).
   PubMed Web of Science ®Google Scholar
• Batt DG , QiaoJX, ModiDPet al. 5-amidinoindoles as dual inhibitors of coagulation Factors IXa and Xa. Bioorg. Med. Chem. Lett.14 (21), 5269–5273 (2004).
   PubMed Web of Science ®Google Scholar
• Qiao JX , ChengX, ModiDPet al. 5-amidinobenzo[b]thiophenes as dual inhibitors of Factors IXa and Xa. Bioorg. Med. Chem. Lett.15 (1), 29–35 (2005).
   PubMed Web of Science ®Google Scholar
• Abdel-Magid AF . Inhibitors of Factor XIa and plasma kallikrein may treat thromboembolic disorders and many diabetes complications. ACS Med. Chem. Lett.5 (4), 286–287 (2014).
   PubMedGoogle Scholar
• Savi P , HeraultJP, DuchaussoyPet al. Reversible biotinylated oligosaccharides: a new approach for a better management of anticoagulant therapy. J. Thromb. Haemost.6 (10), 1697–1706 (2008).
   PubMed Web of Science ®Google Scholar
• Olson ST , SwansonR, PetitouM. Specificity and selectivity profile of EP217609: a new neutralizable dual-action anticoagulant that targets thrombin and Factor Xa. Blood119 (10), 2187–2195 (2012).
   PubMed Web of Science ®Google Scholar
• Kaeberich A , RaazU, VogtAet al. In vitro comparison of the novel, dual-acting FIIa/FXa-inhibitor EP217609C101, unfractionated heparin, enoxaparin, and fondaparinux in preventing cardiac catheter thrombosis. J. Thromb. Thrombolysis37 (2), 118–130 (2014).
   PubMed Web of Science ®Google Scholar
• Alame G , ManginPH, FreundMet al. EP217609, a neutralisable dual-action FIIa/FXa anticoagulant, with antithrombotic effects in arterial thrombosis. Thromb. Haemost.113 (2), 385–395 (2014).
   PubMed Web of Science ®Google Scholar
• Shirk RA , VlasukGP. Inhibitors of Factor VIIa/tissue factor. Arterioscler. Thromb. Vasc. Biol.27 (9), 1895–1900 (2007).
   PubMed Web of Science ®Google Scholar
• Larsen KS , OstergaardH, BjelkeJRet al. Engineering the substrate and inhibitor specificities of human coagulation Factor VIIa. Biochem. J.405 (3), 429–438 (2007).
   PubMedGoogle Scholar
• Henry BL , Abdel AzizM, ZhouQ, DesaiUR. Sulfated, low-molecular-weight lignins are potent inhibitors of plasmin, in addition to thrombin and Factor Xa: novel opportunity for controlling complex pathologies. Thromb. Haemost.103 (3), 507–515 (2010).
   PubMed Web of Science ®Google Scholar
• Hirayama F , KoshioH, KatayamaNet al. The discovery of YM-60828: a potent, selective and orally-bioavailable Factor Xa inhibitor. Biorg. Med. Chem.10 (5), 1509–1523 (2002).
   PubMed Web of Science ®Google Scholar
• Verner E , KatzBA, SpencerJRet al. Development of serine protease inhibitors displaying a multicentered short (<2.3 Å) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and Factor Xa. J. Med. Chem.44 (17), 2753–2771 (2001).
   PubMed Web of Science ®Google Scholar
• Feener EP . Plasma kallikrein and diabetic macular edema. Curr. Diab. Rep.10 (4), 270–275 (2010).
   PubMed Web of Science ®Google Scholar
• Feener EP , ZhouQ, FickweilerW. Role of plasma kallikrein in diabetes and metabolism. Thromb. Haemost.110 (3), 434–441 (2013).
   PubMed Web of Science ®Google Scholar
• Corte JR , FangT, DeciccoCPet al. WO2011100401 (2011).
   Google Scholar
• Lam PYS , ClarkCG, CorteJRet al. WO2013022814 (2013).
   Google Scholar
• Yang W , GilliganPJ, Pinto PintoDJP, EwingWR, WangY. WO2014022766 (2014).
   Google Scholar
• Hauel NH , NarH, PriepkeH, RiesU, StassenJM, WienenW. Structure-based design of novel potent nonpeptide thrombin inhibitors. J. Med. Chem.45 (9), 1757–1766 (2002).
   PubMed Web of Science ®Google Scholar
• Francischetti IMB . Platelet aggregation inhibitors from hematophagous animals. Toxicon56 (7), 1130–1144 (2010).
   PubMed Web of Science ®Google Scholar
• Markwardt F . State-of-the-art review: antithrombotic agents from hematophagous animals. Clin. Appl. Thromb. Hemost.2 (2), 75–82 (1996).
   Web of Science ®Google Scholar
• Petros S . Lepirudin in the management of patients with heparin-induced thrombocytopenia. Biologics2 (3), 481–490 (2008).
   PubMedGoogle Scholar
• Fisher M , LoscalzoJ. The perils of combination antithrombotic therapy and potential resolutions. Stroke42 (2), 278–281 (2011).
   PubMed Web of Science ®Google Scholar
• Guglielmone HA , AgneseAM, Núñez MontoyaSC, CabreraJL. Anticoagulant effect and action mechanism of sulphated flavonoids from Flaveria bidentis. Thromb. Res.105 (2), 183–188 (2002).
   PubMed Web of Science ®Google Scholar
• Guglielmone HA , AgneseAM, Núñez MontoyaSC, CabreraJL. Inhibitory effects of sulphated flavonoids isolated from Flaveria bidentis on platelet aggregation. Thromb. Res.115 (6), 495–502 (2005).
   PubMed Web of Science ®Google Scholar
• Correia-Da-Silva M , SousaE, DuarteB, MarquesF, Cunha-RibeiroLM, PintoMMM. Dual anticoagulant/antiplatelet persulfated small molecules. Eur. J. Med. Chem.46 (6), 2347–2358 (2011).
   PubMed Web of Science ®Google Scholar
• Correia-Da-Silva M , SousaEL, DuarteBRet al. Polysulfated xanthones: multipathway development of a new generation of dual anticoagulant/antiplatelet agents. J. Med. Chem.54 (15), 5373–5384 (2011).
   PubMed Web of Science ®Google Scholar
• Rashid Q , AbidM, GuptaN, TyagiT, AshrafMZ, JairajpuriMA. Polysulfated trehalose as a novel anticoagulant agent with dual mode of action. Biomed Res. Int.2015, 11 (2015).
   Web of Science ®Google Scholar
• Stefanic Anderluh P , AnderluhM, IlasJet al. Toward a novel class of antithrombotic compounds with dual function. Discovery of 1,4-benzoxazin-3(4H)-one derivatives possessing thrombin inhibitory and fibrinogen receptor antagonistic activities. J. Med. Chem.48 (9), 3110–3113 (2005).
   PubMed Web of Science ®Google Scholar
• Ilaš J , JakopinŽ, BorštnarT, StegnarM, KikeljD. 3,4-dihydro-2h-1,4-benzoxazine derivatives combining thrombin inhibitory and glycoprotein IIb/IIIa receptor antagonistic activity as a novel class of antithrombotic compounds with dual function. J. Med. Chem.51 (18), 5617–5629 (2008).
   PubMed Web of Science ®Google Scholar
• De Candia M , LiantonioF, CarottiA, De CristofaroR, AltomareC. Fluorinated benzyloxyphenyl piperidine-4-carboxamides with dual function against thrombosis: inhibitors of Factor Xa and platelet aggregation. J. Med. Chem.52 (4), 1018–1028 (2009).
   PubMed Web of Science ®Google Scholar
• Haque W . US6417204 (2002).
   Google Scholar
• Haque W . US11016737 (2008).
   Google Scholar
• Haque W , DiakurJ, PhamVet al. US7812037 (2010).
   Google Scholar
• Hechler B , FreundM, AlameGet al. The antithrombotic activity of EP224283, a neutralizable dual Factor Xa inhibitor/glycoprotein IIbIIIa antagonist, exceeds that of the coadministered parent compounds. J. Pharmacol. Exp. Ther.338 (2), 412–420 (2011).
   PubMed Web of Science ®Google Scholar
• Kuo HL , LienJC, ChungCHet al. NP-184[2-(5-methyl-2-furyl) benzimidazole], a novel orally active antithrombotic agent with dual antiplatelet and anticoagulant activities. Naunyn Schmiedebergs Arch. Pharmacol.381 (6), 495–505 (2010).
   PubMed Web of Science ®Google Scholar
• Trstenjak U , IlašJ, KikeljD. Low molecular weight dual inhibitors of Factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores. Eur. J. Med. Chem.64, 302–313 (2013).
   PubMed Web of Science ®Google Scholar
• Mehta AY , ThakkarJN, MohammedBMet al. Targeting the GPIbα binding site of thrombin to simultaneously induce dual anticoagulant and antiplatelet effects. J. Med. Chem.57 (7), 3030–3039 (2014).
   PubMed Web of Science ®Google Scholar
• Correia-Da-Silva M , SousaE, DuarteBet al. Flavonoids with an oligopolysulfated moiety: a new class of anticoagulant agents. J. Med. Chem.54 (1), 95–106 (2011).
   PubMed Web of Science ®Google Scholar
• Mehta AY , MohammedBM, MartinEJ, BrophyDF, GailaniD, DesaiUR. Allosterism-based simultaneous, dual anticoagulant and antiplatelet action: allosteric inhibitor targeting the glycoprotein Ibα and heparin-binding site of thrombin. J. Thromb. Haemost.14 (4), 828–838 (2016).
   PubMed Web of Science ®Google Scholar
• Andrews RK , BerndtMC. Platelet physiology and thrombosis. Thromb. Res.114 (5–6), 447–453 (2004).
   PubMedGoogle Scholar
• Terpening C . An appraisal of dual antiplatelet therapy with clopidogrel and aspirin for prevention of cardiovascular events. J. Am. Board Fam. Med.22 (1), 51–56 (2009).
   PubMed Web of Science ®Google Scholar
• Reaume KT , RegalRE, DorschMP. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use. Ann. Pharmacother.42 (4), 550–557 (2008).
   PubMed Web of Science ®Google Scholar
• Mehta SR , YusufS, PetersRJGet al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet358 (9281), 527–533 (2001).
   PubMed Web of Science ®Google Scholar
• Mulukutla SR , MarroquinOC, VlachosHAet al. Benefit of long-term dual anti-platelet therapy in patients treated with drug-eluting stents: from the NHLBI dynamic registry. Am. J. Cardiol.111 (4), 486–492 (2013).
   PubMed Web of Science ®Google Scholar
• Pan C , WeiX, YeJet al. BF066, a novel dual target antiplatelet agent without significant bleeding. PLoS ONE7 (7), e40451 (2012).
   PubMed Web of Science ®Google Scholar
• Ogletree ML . Overview of physiological and pathophysiological effects of thromboxane A2. Fed. Proc.46 (1), 133–138 (1987).
   PubMedGoogle Scholar
• Gresele P , DeckmynH, ArnoutJ, NenciGG, VermylenJ. Characterization of N,N´-bis(3-picolyl)-4-methoxy-isophtalamide (picotamide) as a dual thromboxane synthase inhibitor/thromboxane A2 receptor antagonist in human platelets. Thromb. Haemost.61 (3), 479–484 (1989).
   PubMed Web of Science ®Google Scholar
• Mearns BM . Antiplatelet therapy: terutroban does not out-PERFORM aspirin in secondary prevention. Nat. Rev. Cardiol.8 (8), 423–423 (2011).
   PubMedGoogle Scholar
• Ghuysen A , LambermontB, DogneJMet al. Effect of BM-573 [N-terbutyl-N´-[2-(4′-methylphenylamino)-5-nitro-benzenesulfonyl]urea], a dual thromboxane synthase inhibitor and thromboxane receptor antagonist, in a porcine model of acute pulmonary embolism. J. Pharmacol. Exp. Ther.310 (3), 964–972 (2004).
   PubMed Web of Science ®Google Scholar
• Ghuysen A , DognéJ-M, ChiapPet al. Pharmacological profile and therapeutic potential of BM-573, a combined thromboxane receptor antagonist and synthase inhibitor. Cardiovasc. Drug Rev.23 (1), 1–14 (2005).
   PubMedGoogle Scholar
• Hanson J , RolinS, ReynaudDet al. In vitro and in vivo pharmacological characterization of BM-613 [N-n-pentyl-N´-[2-(4′-methylphenylamino)-5-nitrobenzenesulfonyl]urea], a novel dual thromboxane synthase inhibitor and thromboxane receptor antagonist. J. Pharmacol. Exp. Ther.313 (1), 293–301 (2005).
   PubMed Web of Science ®Google Scholar
• Jin YR , ChoMR, RyuCKet al. Antiplatelet activity of J78 (2-Chloro-3-[2′-bromo, 4′-fluoro-phenyl]-amino-8-hydroxy-1,4-naphthoquinone), an antithrombotic agent, is mediated by thromboxane (TX) A2 receptor blockade with TXA2 synthase inhibition and suppression of cytosolic Ca2+ mobilization. J. Pharmacol. Exp. Ther.312 (1), 214–219 (2005).
   PubMed Web of Science ®Google Scholar
• Jin YR , ChoMR, LeeKSet al. An antithrombotic agent, NQ301, inhibits thromboxane A2 receptor and synthase activity in rabbit platelets. Basic Clin. Pharmacol. Toxicol.97 (3), 162–167 (2005).
   PubMed Web of Science ®Google Scholar
• Kuo HL , LienJC, ChangCHet al. NP-313, 2-acetylamino-3-chloro-1,4-naphthoquinone, a novel antithrombotic agent with dual inhibition of thromboxane A(2) synthesis and calcium entry. Br. J. Pharmacol.162 (8), 1871–1883 (2011).
   PubMed Web of Science ®Google Scholar
• Ohno M , MiyamotoM, HoshiK, TakedaT, YamadaN, OhtakeA. Development of dual-acting benzofurans for thromboxane A2 receptor antagonist and prostacyclin receptor agonist: synthesis, structure–activity relationship, and evaluation of benzofuran derivatives. J. Med. Chem.48 (16), 5279–5294 (2005).
   PubMed Web of Science ®Google Scholar
• Ohno M , TanakaY, MiyamotoMet al. Development of 3,4-dihydro-2H-benzo[1,4]oxazine derivatives as dual thromboxane A2 receptor antagonists and prostacyclin receptor agonists. Biorg. Med. Chem.14 (6), 2005–2021 (2006).
   PubMed Web of Science ®Google Scholar
• Zhang S , HuL, DuHet al. BF0801, a novel adenine derivative, inhibits platelet activation via phosphodiesterase inhibition and P2Y12 antagonism. Thromb. Haemost.104 (4), 845–857 (2010).
   PubMed Web of Science ®Google Scholar
• Hu L , FanZ, DuHet al. BF061, a novel antiplatelet and antithrombotic agent targeting P2Y12 receptor and phosphodiesterase. Thromb. Haemost.106 (12), 1203–1214 (2011).
   PubMedGoogle Scholar
• Lien JC , WuCR, HourMJ, HuangLJ, HuangTF, KuoSC. Synthesis of 2,3-disubstituted 1,4-naphthoquinones as antiplatelet agents. Arch. Pharm.341 (10), 639–644 (2008).
   PubMed Web of Science ®Google Scholar
• Lien JC , HuangLJ, TengCM, WangJP, KuoSC. Synthesis of 2-alkoxy 1,4-naphthoquinone derivatives as antiplatelet, antiinflammatory, and antiallergic agents. Chem. Pharm. Bull.50 (5), 672–674 (2002).
   PubMed Web of Science ®Google Scholar
• Jin YR , HwangKA, ChoMRet al. Antiplatelet and antithrombotic activities of CP201, a newly synthesized 1,4-naphthoquinone derivative. Vascul. Pharmacol.41 (1), 35–41 (2004).
   PubMed Web of Science ®Google Scholar
• Jin YR , RyuCK, MoonCK, ChoMR, YunYP. Inhibitory effects of J78, a newly synthesized 1,4-naphthoquinone derivative, on experimental thrombosis and platelet aggregation. Pharmacology70 (4), 195–200 (2004).
   PubMed Web of Science ®Google Scholar
• Kang WS , RyuCK, ChungKHet al. Antiplatelet and antithrombotic activities of NQ301, 2-chloro-3-(4-acetophenyl)-amino-1,4-naphthoquinone. Biol. Pharm. Bull.22 (12), 1284–1287 (1999).
   PubMed Web of Science ®Google Scholar
• Im JH , FuW, WangHet al. Coagulation facilitates tumor cell spreading in the pulmonary vasculature during early metastatic colony formation. Cancer Res.64 (23), 8613–8619 (2004).
   PubMed Web of Science ®Google Scholar
• Levi M , Van Der PollT, BüllerHR. Bidirectional relation between inflammation and coagulation. Circulation109 (22), 2698–2704 (2004).
   PubMed Web of Science ®Google Scholar
• Donati MB . Thrombosis and cancer: trousseau syndrome revisited. Best Pract. Res. Clin. Haematol.22 (1), 3–8 (2009).
   PubMed Web of Science ®Google Scholar
• Gunnarsson GT , RiazM, AdamsJ, DesaiUR. Synthesis of per-sulfated flavonoids using 2,2,2-trichloro ethyl protecting group and their Factor Xa inhibition potential. Biorg. Med. Chem.13 (5), 1783–1789 (2005).
   PubMed Web of Science ®Google Scholar
• Raman K , KaruturiR, SwarupVP, DesaiUR, KuberanB. Discovery of novel sulfonated small molecules that inhibit vascular tube formation. Bioorg. Med. Chem. Lett.22 (13), 4467–4470 (2012).
   PubMed Web of Science ®Google Scholar
• Muro S , MuzykantovV. Targeting of antioxidant and anti-thrombotic drugs to endothelial cell adhesion molecules. Curr. Pharm. Des.11 (18), 2383–2401 (2005).
   PubMed Web of Science ®Google Scholar
• Bi W , BiL, CaiJet al. Dual-acting agents that possess free radical scavenging and antithrombotic activities: design, synthesis, and evaluation of phenolic tetrahydro-beta-carboline RGD peptide conjugates. Bioorg. Med. Chem. Lett.16 (17), 4523–4527 (2006).
   PubMed Web of Science ®Google Scholar
• Bi W , CaiJ, LiuS, Baudy-Floc’hM, BiL. Design, synthesis and cardioprotective effect of a new class of dual-acting agents: phenolic tetrahydro-β-carboline RGD peptidomimetic conjugates. Biorg. Med. Chem.15 (22), 6909–6919 (2007).
   PubMed Web of Science ®Google Scholar
• Thalassitis A , Hadjipavlou-LitinaDJ, LitinasKE, MiltiadouP. Synthesis of modified homo-N-nucleosides from the reactions of mesityl nitrile oxide with 9-allylpurines and their influence on lipid peroxidation and thrombin inhibition. Bioorg. Med. Chem. Lett.19 (22), 6433–6436 (2009).
   PubMed Web of Science ®Google Scholar
• Park ES , LimY, LeeSHet al. Antiplatelet activity of obovatol, a biphenolic component of magnolia obovata, in rat arterial thrombosis and rabbit platelet aggregation. J. Artheroscler. Thromb.18 (8), 659–669 (2011).
   PubMed Web of Science ®Google Scholar
• Ilić M , KontogiorgisC, Hadjipavlou-LitinaD, IlašJ, KikeljD. Thrombin inhibitors with lipid peroxidation and lipoxygenase inhibitory activities. Bioorg. Med. Chem. Lett.21 (16), 4705–4709 (2011).
   PubMed Web of Science ®Google Scholar
• Da Silva MC , CidadeH, SousaE, PintoM. Searching for small molecules with antioxidant and anticoagulant properties to fight thrombosis. Am. J. Pharm. Sci. Nano.1 (1), 43–50 (2014).
   Google Scholar
• Kontogiorgis C , NicolottiO, MangiatordiGFet al. Studies on the antiplatelet and antithrombotic profile of anti-inflammatory coumarin derivatives. J. Enzyme Inhib. Med. Chem.30 (6), 925–933 (2015).
   PubMed Web of Science ®Google Scholar
• Kontogiorgis CA , Hadjipavlou-LitinaDJ. Synthesis and biological evaluation of novel coumarin derivatives with a 7-azomethine linkage. Bioorg. Med. Chem. Lett.14 (3), 611–614 (2004).
   PubMed Web of Science ®Google Scholar
• Kontogiorgis CA , Hadjipavlou-LitinaDJ. Synthesis and antiinflammatory activity of coumarin derivatives. J. Med. Chem.48 (20), 6400–6408 (2005).
   PubMed Web of Science ®Google Scholar
• Kontogiorgis CA , SavvoglouK, Hadjipavlou-LitinaDJ. Antiinflammatory and antioxidant evaluation of novel coumarin derivatives. J. Enzyme Inhib. Med. Chem.21 (1), 21–29 (2006).
   PubMed Web of Science ®Google Scholar
• Matsuda H , KageuraT, OdaM, MorikawaT, SakamotoY, YoshikawaM. Effects of constituents from the bark of Magnolia obovata on nitric oxide production in lipopolysaccharide-activated macrophages. Chem. Pharm. Bull. (Tokyo)49 (6), 716–720 (2001).
   PubMed Web of Science ®Google Scholar